U.S. markets closed

Gossamer Bio, Inc. (GOSS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
8.98+0.04 (+0.45%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
Previous Close8.94
Open9.00
Bid8.84 x 800
Ask9.08 x 1000
Day's Range8.82 - 9.05
52 Week Range7.52 - 27.15
Volume239,067
Avg. Volume764,717
Market Cap681.833M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.56
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer

    Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that the Company’s Board of Directors has appointed Faheem Hasnain as Chief Executive Officer and President, effective immediately. Mr. Hasnain is a Co-Founder, former Chief Executive Officer, and current Chairman of Gossamer Bio. Mr. Hasnain succeeds Sheila Gujrathi, M.D., a Co-Founder of Gossamer Bio, who served as Chief Executive Officer and President since July 2018. Dr. Gujrathi will continue in an advisory role to the Company.

  • Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
    Business Wire

    Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update

    Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the third quarter of 2020 and provided a corporate update.

  • ACCESSWIRE

    Gossamer Bio, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 10, 2020 / Gossamer Bio, Inc.